The global chronic kidney disease market was valued at USD 20.65 billion in 2025. The market is estimated at USD 21.90 billion in 2026 and is projected to reach USD 44.72 billion by 2036, at a CAGR of 7.4% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering epidemiology, therapies and diagnostics, regulation, reimbursement, the pipeline, pricing, competition, and growth opportunities.
The market covers medicines for chronic kidney disease and its metabolic complications, plus diagnostic and monitoring tests. Kidney-protective drugs include SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs), GLP-1 receptor agonists, renin-angiotensin blockers, endothelin receptor antagonists, complement inhibitors, glomerular immunomodulators, and vasopressin antagonists. Complication therapies treat anemia, mineral and bone disorder, hyperkalemia, metabolic acidosis, and pruritus, and testing spans eGFR, cystatin C, urine albumin-to-creatinine ratio (UACR), biopsy, and imaging. Dialysis, transplantation, and acute kidney injury therapies are excluded.
According to the GBD 2023 study published in The Lancet in November 2.02 trillion adults had chronic kidney disease in 2023, up from 378 million in 1990, and the condition caused 1.48 million deaths, ranking ninth among causes of death worldwide. In the U.S., Medicare spending on chronic kidney disease short of kidney failure reached nearly USD 77 billion among beneficiaries aged 66 and older in 2021, with kidney failure adding USD 52.3 billion. According to the Centers for Disease Control and Prevention, 87% of U.S. adults with the disease do not know they have it.
Loss of exclusivity is the largest restraint on value, as AstraZeneca reported Farxiga first-half 2026 revenue down 11% at constant exchange rates on U.S. generics and Chinese volume-based procurement, which also hit roxadustat. Medicare maximum fair prices for Farxiga and Jardiance took effect in 2026 at about two-thirds below 2023 list prices, and low testing rates leave many patients untreated. Complication therapy suppliers face bundling of oral renal drugs into U.S. dialysis payments and generic erosion in anemia and mineral metabolism, shown by CSL's large impairment of CSL Vifor. Trial attrition, such as the VALOR-CKD failure of veverimer, limited cystatin C testing, and high out-of-pocket costs in emerging markets add challenges.
The biggest opportunity lies in treating eligible patients not yet on therapy; according to an Australian primary care analysis, only 14.4% of adults with type 2 diabetes and chronic kidney disease received an SGLT2 inhibitor. Non-diabetic disease is another branded opening, as Bayer estimates that 50% to 70% of affected U.S. adults do not have diabetes, and its FIND-CKD trial showed slower eGFR decline in this group. Payment-linked quality measures such as the Kidney Health Evaluation and cell therapies such as ProKidney's rilparencel add potential. Key trends include eGFR slope as a surrogate endpoint, crowding in IgA nephropathy, race-free and cystatin C-based kidney function equations, home albuminuria tests, and portfolio realignment among renal specialists.
By treatment type, the chronic kidney disease market is segmented into disease-modifying & kidney-protective therapies, complication-management therapies, and diagnosis & monitoring. Disease-modifying & kidney-protective therapies are expected to hold the largest share in 2026, given the sales scale of SGLT2 inhibitors, non-steroidal MRAs, and GLP-1 receptor agonists, their strong guideline backing, and long-term daily use; Bayer reported Kerendia first-half sales up 75.3%. Diagnosis & monitoring is expected to grow at the highest CAGR, as the Kidney Health Evaluation measure requires yearly eGFR and UACR tests in diabetes, albuminuria testing remains uncommon in at-risk adults, and home tests make screening easier. Complication therapies face generic pressure, and metabolic acidosis still has no approved treatment.
By molecule type, the chronic kidney disease market is segmented into small molecules, biologics, peptides, polymers and binders, and cell and gene therapies. Small molecules are expected to account for the largest share in 2026, as SGLT2 inhibitors, non-steroidal MRAs, endothelin receptor antagonists, factor B inhibitors, and HIF prolyl hydroxylase inhibitors are oral drugs used in large patient groups. Biologics are expected to grow the fastest, led by APRIL and BAFF pathway agents in IgA nephropathy, including Otsuka's sibeprenlimab, approved in November 2025, Vera Therapeutics' atacicept, approved in July 2026, and Vertex's povetacicept, under FDA review. Cell therapies remain early, though ProKidney's rilparencel is in Phase 3.
By disease stage, the chronic kidney disease market is segmented into stage 1 and stage 2, stage 3a, stage 3b, stage 4, and stage 5 chronic kidney disease not on dialysis. Stage 3a and stage 3b together are expected to account for the largest share in 2026, as most patients sit in the earlier stages and KDIGO recommends SGLT2 inhibitors down to an eGFR of 20. Stage 1 and stage 2 disease is expected to grow at the highest CAGR, helped by albuminuria screening and a KDIGO risk model that rates severe albuminuria as high or very high risk even with preserved kidney function. Stage 4 and stage 5 patients not on dialysis remain a target for drugs that delay kidney replacement therapy.
By route of administration, the chronic kidney disease market is segmented into oral, intravenous, subcutaneous, and other routes. Oral therapies are expected to hold the largest share in 2026, since all major kidney-protective classes and most phosphate binders, potassium binders, and HIF prolyl hydroxylase inhibitors are taken by mouth, which suits long-term community prescribing. The subcutaneous route is expected to post the highest CAGR, driven by GLP-1 receptor agonists with KDIGO grade 1B support and new glomerular biologics such as weekly atacicept by autoinjector and povetacicept dosed every four weeks. Intravenous iron brands such as Ferinject and Venofer face generic entry.
By distribution channel, the chronic kidney disease market is segmented into hospital pharmacies, retail pharmacies, specialty pharmacies, dialysis and nephrology clinic dispensing, and online pharmacies. Retail pharmacies are expected to hold the largest share in 2026, reflecting long-term oral prescribing in the community, including high SGLT2 inhibitor volumes now sold at Medicare negotiated prices. Specialty pharmacies are expected to grow the fastest, as costly orphan drugs for glomerular disease need benefit checks, patient support, and controlled supply, as with Vera Therapeutics' copay program for atacicept and the safety program for iptacopan. Clinic dispensing is shaped by the inclusion of oral renal drugs in the U.S. dialysis payment bundle since 2025.
By end user, the chronic kidney disease market is segmented into hospitals, specialty and ambulatory clinics, primary care and community health settings, dialysis and renal care centers, diagnostic laboratories, and home care settings. Specialty and ambulatory clinics are expected to hold the largest share in 2026, as nephrology prescribing and glomerular disease care, including biopsy and proteinuria monitoring, take place mainly in specialist outpatient settings. Primary care and community health settings are expected to grow at the highest CAGR, as case finding and first-line prescribing move to primary care under the Kidney Health Evaluation measure, and much advanced disease still goes undetected there. Laboratories gain from guideline support for cystatin C, though few have adopted the combined equation.
North America is expected to hold the largest share of the chronic kidney disease market in 2026, supported by higher drug prices, wide formulary coverage for kidney-protective drugs, and the concentration of glomerular disease launches in the U.S., where, according to the Centers for Disease Control and Prevention, about 37 million adults have stage 1 to 4 disease. Medicare negotiated prices for Farxiga and Jardiance from 2026, with semaglutide to follow in 2027, add pricing pressure.
Asia-Pacific is expected to register the highest CAGR, supported by its large patient base and wider reimbursement. An Indian parliamentary committee report of August 2026 called for a national strategy for the disease, and China's 2025 National Reimbursement Drug List added 114 drugs from January 2026, while Japanese checkup data showed fewer than one in four affected people had a recorded diagnosis. Europe holds a significant share, shaped by structured health technology assessment such as NICE's 2025 recommendation of dapagliflozin. Latin America is held back by narrow public access to SGLT2 inhibitors in Brazil, while the Middle East & Africa includes North Africa and the Middle East, the region with the highest prevalence in GBD 2023, but has weak financial protection.
The chronic kidney disease market is moderately fragmented, with large cardio-renal-metabolic drug makers competing alongside nephrology specialists, glomerular disease developers, renal anemia suppliers, generic makers, and diagnostics firms on outcome evidence, guideline grades, label breadth, reimbursement, exclusivity, and patient support. Recent activity includes Biogen's acquisition of Apellis Pharmaceuticals in May 2026, Travere's in-licensing of civorebrutinib from Everest Medicines in July 2026, Asahi Kasei's integration of Calliditas, the sale of FibroGen China to AstraZeneca, and Novartis' atrasentan filings in the U.S. and EU.
Key companies profiled in the report include AstraZeneca PLC (U.K.), Bayer AG (Germany), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Eli Lilly and Company (U.S.), Otsuka Pharmaceutical Co., Ltd. (Japan), Vera Therapeutics, Inc. (U.S.), Vertex Pharmaceuticals Incorporated (U.S.), Novo Nordisk A/S (Denmark), Travere Therapeutics, Inc. (U.S.), Akebia Therapeutics, Inc. (U.S.), Ardelyx, Inc. (U.S.), GSK plc (U.K.), Roche Holding AG (Switzerland), Kyowa Kirin Co., Ltd. (Japan), Astellas Pharma Inc. (Japan), and CSL Limited (Australia).
The market covers medicines for chronic kidney disease and its metabolic complications, plus diagnostic and monitoring tests. Kidney-protective drugs include SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs), GLP-1 receptor agonists, renin-angiotensin blockers, endothelin receptor antagonists, complement inhibitors, glomerular immunomodulators, and vasopressin antagonists. Complication therapies treat anemia, mineral and bone disorder, hyperkalemia, metabolic acidosis, and pruritus, and testing spans eGFR, cystatin C, urine albumin-to-creatinine ratio (UACR), biopsy, and imaging. Dialysis, transplantation, and acute kidney injury therapies are excluded.
According to the GBD 2023 study published in The Lancet in November 2.02 trillion adults had chronic kidney disease in 2023, up from 378 million in 1990, and the condition caused 1.48 million deaths, ranking ninth among causes of death worldwide. In the U.S., Medicare spending on chronic kidney disease short of kidney failure reached nearly USD 77 billion among beneficiaries aged 66 and older in 2021, with kidney failure adding USD 52.3 billion. According to the Centers for Disease Control and Prevention, 87% of U.S. adults with the disease do not know they have it.
Market Dynamics
Rising prevalence is the main driver of the chronic kidney disease market, with most affected adults in the earlier stages, where drugs can change the course of the disease. Payers are pushing to delay kidney failure, which costs far more than prevention, and a 2021 meta-analysis reported that SGLT2 inhibitors cut the risk of progression by 37%. Glomerular disease treatment has expanded quickly, with Novartis gaining traditional U.S. approval for Fabhalta in IgA nephropathy in July 2026 and Travere winning approval for Filspari in focal segmental glomerulosclerosis in April 2026. Label expansions, such as Bayer's third Kerendia indication in September 2026, and the KDIGO 2024 guideline's grade 1A support for SGLT2 inhibitors in diabetic and non-diabetic disease widen the eligible population.Loss of exclusivity is the largest restraint on value, as AstraZeneca reported Farxiga first-half 2026 revenue down 11% at constant exchange rates on U.S. generics and Chinese volume-based procurement, which also hit roxadustat. Medicare maximum fair prices for Farxiga and Jardiance took effect in 2026 at about two-thirds below 2023 list prices, and low testing rates leave many patients untreated. Complication therapy suppliers face bundling of oral renal drugs into U.S. dialysis payments and generic erosion in anemia and mineral metabolism, shown by CSL's large impairment of CSL Vifor. Trial attrition, such as the VALOR-CKD failure of veverimer, limited cystatin C testing, and high out-of-pocket costs in emerging markets add challenges.
The biggest opportunity lies in treating eligible patients not yet on therapy; according to an Australian primary care analysis, only 14.4% of adults with type 2 diabetes and chronic kidney disease received an SGLT2 inhibitor. Non-diabetic disease is another branded opening, as Bayer estimates that 50% to 70% of affected U.S. adults do not have diabetes, and its FIND-CKD trial showed slower eGFR decline in this group. Payment-linked quality measures such as the Kidney Health Evaluation and cell therapies such as ProKidney's rilparencel add potential. Key trends include eGFR slope as a surrogate endpoint, crowding in IgA nephropathy, race-free and cystatin C-based kidney function equations, home albuminuria tests, and portfolio realignment among renal specialists.
Segment Analysis
The report analyzes the market by treatment type, molecule type, disease stage, route of administration, distribution channel, end user, and geography, helping stakeholders identify the most attractive areas for development, launch, and investment.By treatment type, the chronic kidney disease market is segmented into disease-modifying & kidney-protective therapies, complication-management therapies, and diagnosis & monitoring. Disease-modifying & kidney-protective therapies are expected to hold the largest share in 2026, given the sales scale of SGLT2 inhibitors, non-steroidal MRAs, and GLP-1 receptor agonists, their strong guideline backing, and long-term daily use; Bayer reported Kerendia first-half sales up 75.3%. Diagnosis & monitoring is expected to grow at the highest CAGR, as the Kidney Health Evaluation measure requires yearly eGFR and UACR tests in diabetes, albuminuria testing remains uncommon in at-risk adults, and home tests make screening easier. Complication therapies face generic pressure, and metabolic acidosis still has no approved treatment.
By molecule type, the chronic kidney disease market is segmented into small molecules, biologics, peptides, polymers and binders, and cell and gene therapies. Small molecules are expected to account for the largest share in 2026, as SGLT2 inhibitors, non-steroidal MRAs, endothelin receptor antagonists, factor B inhibitors, and HIF prolyl hydroxylase inhibitors are oral drugs used in large patient groups. Biologics are expected to grow the fastest, led by APRIL and BAFF pathway agents in IgA nephropathy, including Otsuka's sibeprenlimab, approved in November 2025, Vera Therapeutics' atacicept, approved in July 2026, and Vertex's povetacicept, under FDA review. Cell therapies remain early, though ProKidney's rilparencel is in Phase 3.
By disease stage, the chronic kidney disease market is segmented into stage 1 and stage 2, stage 3a, stage 3b, stage 4, and stage 5 chronic kidney disease not on dialysis. Stage 3a and stage 3b together are expected to account for the largest share in 2026, as most patients sit in the earlier stages and KDIGO recommends SGLT2 inhibitors down to an eGFR of 20. Stage 1 and stage 2 disease is expected to grow at the highest CAGR, helped by albuminuria screening and a KDIGO risk model that rates severe albuminuria as high or very high risk even with preserved kidney function. Stage 4 and stage 5 patients not on dialysis remain a target for drugs that delay kidney replacement therapy.
By route of administration, the chronic kidney disease market is segmented into oral, intravenous, subcutaneous, and other routes. Oral therapies are expected to hold the largest share in 2026, since all major kidney-protective classes and most phosphate binders, potassium binders, and HIF prolyl hydroxylase inhibitors are taken by mouth, which suits long-term community prescribing. The subcutaneous route is expected to post the highest CAGR, driven by GLP-1 receptor agonists with KDIGO grade 1B support and new glomerular biologics such as weekly atacicept by autoinjector and povetacicept dosed every four weeks. Intravenous iron brands such as Ferinject and Venofer face generic entry.
By distribution channel, the chronic kidney disease market is segmented into hospital pharmacies, retail pharmacies, specialty pharmacies, dialysis and nephrology clinic dispensing, and online pharmacies. Retail pharmacies are expected to hold the largest share in 2026, reflecting long-term oral prescribing in the community, including high SGLT2 inhibitor volumes now sold at Medicare negotiated prices. Specialty pharmacies are expected to grow the fastest, as costly orphan drugs for glomerular disease need benefit checks, patient support, and controlled supply, as with Vera Therapeutics' copay program for atacicept and the safety program for iptacopan. Clinic dispensing is shaped by the inclusion of oral renal drugs in the U.S. dialysis payment bundle since 2025.
By end user, the chronic kidney disease market is segmented into hospitals, specialty and ambulatory clinics, primary care and community health settings, dialysis and renal care centers, diagnostic laboratories, and home care settings. Specialty and ambulatory clinics are expected to hold the largest share in 2026, as nephrology prescribing and glomerular disease care, including biopsy and proteinuria monitoring, take place mainly in specialist outpatient settings. Primary care and community health settings are expected to grow at the highest CAGR, as case finding and first-line prescribing move to primary care under the Kidney Health Evaluation measure, and much advanced disease still goes undetected there. Laboratories gain from guideline support for cystatin C, though few have adopted the combined equation.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 19 country-level markets (with Australia & New Zealand assessed together) and four rest-of-region groups. The regional analysis considers prevalence, diagnosis rates, drug pricing, reimbursement and health technology assessment, and access to new therapies.North America is expected to hold the largest share of the chronic kidney disease market in 2026, supported by higher drug prices, wide formulary coverage for kidney-protective drugs, and the concentration of glomerular disease launches in the U.S., where, according to the Centers for Disease Control and Prevention, about 37 million adults have stage 1 to 4 disease. Medicare negotiated prices for Farxiga and Jardiance from 2026, with semaglutide to follow in 2027, add pricing pressure.
Asia-Pacific is expected to register the highest CAGR, supported by its large patient base and wider reimbursement. An Indian parliamentary committee report of August 2026 called for a national strategy for the disease, and China's 2025 National Reimbursement Drug List added 114 drugs from January 2026, while Japanese checkup data showed fewer than one in four affected people had a recorded diagnosis. Europe holds a significant share, shaped by structured health technology assessment such as NICE's 2025 recommendation of dapagliflozin. Latin America is held back by narrow public access to SGLT2 inhibitors in Brazil, while the Middle East & Africa includes North Africa and the Middle East, the region with the highest prevalence in GBD 2023, but has weak financial protection.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, and market share/rank analysis by key player for 2025, together with company profiles covering business overviews, financial performance, product portfolios, strategic developments, and SWOT analyses.The chronic kidney disease market is moderately fragmented, with large cardio-renal-metabolic drug makers competing alongside nephrology specialists, glomerular disease developers, renal anemia suppliers, generic makers, and diagnostics firms on outcome evidence, guideline grades, label breadth, reimbursement, exclusivity, and patient support. Recent activity includes Biogen's acquisition of Apellis Pharmaceuticals in May 2026, Travere's in-licensing of civorebrutinib from Everest Medicines in July 2026, Asahi Kasei's integration of Calliditas, the sale of FibroGen China to AstraZeneca, and Novartis' atrasentan filings in the U.S. and EU.
Key companies profiled in the report include AstraZeneca PLC (U.K.), Bayer AG (Germany), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Eli Lilly and Company (U.S.), Otsuka Pharmaceutical Co., Ltd. (Japan), Vera Therapeutics, Inc. (U.S.), Vertex Pharmaceuticals Incorporated (U.S.), Novo Nordisk A/S (Denmark), Travere Therapeutics, Inc. (U.S.), Akebia Therapeutics, Inc. (U.S.), Ardelyx, Inc. (U.S.), GSK plc (U.K.), Roche Holding AG (Switzerland), Kyowa Kirin Co., Ltd. (Japan), Astellas Pharma Inc. (Japan), and CSL Limited (Australia).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global chronic kidney disease market.
- Explains how prevalence, payer pressure, glomerular disease approvals, label expansions, and KDIGO guidance shape demand.
- Assesses the impact of generic entry, Medicare negotiated prices, volume-based procurement in China, and low diagnosis rates.
- Identifies high-growth opportunities across treatment type, molecule type, disease stage, route, distribution channel, end user, and region.
- Tracks the IgA nephropathy pipeline, eGFR slope endpoints, and new testing approaches.
- Benchmarks leading companies on portfolios, outcome evidence, launches, and deals.
- Supports portfolio planning, launch strategy, licensing, and market entry decisions for drug developers, diagnostics companies, and investors.
Key Questions Answered
- How big is the global chronic kidney disease market today, and how will it grow through 2036?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How will generic entry and Medicare negotiated prices affect the largest kidney-protective brands?
- How large is the untreated, guideline-eligible patient population, and how can it be reached?
- How is competition in IgA nephropathy and other glomerular diseases changing?
- Which treatment type, molecule type, disease stage, route, distribution channel, and end-user segments will grow the fastest?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies in the market, and how do they compete?
- What acquisitions, licensing deals, and approvals are shaping the competitive landscape?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Chronic Kidney Disease Market, by Treatment Type
6. Chronic Kidney Disease Market, by Molecule Type
7. Chronic Kidney Disease Market, by Disease Stage
8. Chronic Kidney Disease Market, by Route of Administration
9. Chronic Kidney Disease Market, by Distribution Channel
10. Chronic Kidney Disease Market, by End User
11. Chronic Kidney Disease Market, by Geography
12. Competitive Landscape
13. Company Profiles
14. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- AstraZeneca PLC
- Bayer AG
- Novartis AG
- Boehringer Ingelheim International GmbH
- Eli Lilly and Company
- Otsuka Pharmaceutical Co., Ltd.
- Vera Therapeutics, Inc.
- Vertex Pharmaceuticals Incorporated
- Novo Nordisk A/S
- Travere Therapeutics, Inc.
- Akebia Therapeutics, Inc.
- Ardelyx, Inc.
- GSK plc
- Roche Holding AG
- Kyowa Kirin Co., Ltd.
- Astellas Pharma Inc.
- CSL Limited
